Jazz Pharmaceuticals plc Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax
Jazz Pharmaceuticals plc (JAZZ) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax · last filed 2026-08-03
- Jazz Pharmaceuticals plc other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Jazz Pharmaceuticals plc other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2026-03-31 was $100.00K.
- Jazz Pharmaceuticals plc other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2025-12-31 was $80.00K, a 97.85% decline year-over-year.
- Jazz Pharmaceuticals plc other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2025-09-30 was $113.00K.
- Jazz Pharmaceuticals plc other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2025 was $208.00K, a 96.07% decline from fiscal 2024.
- Jazz Pharmaceuticals plc other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2024 was $5.30M, a 44.83% increase from fiscal 2023.
- Jazz Pharmaceuticals plc other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2023 was $3.66M.
- Jazz Pharmaceuticals plc other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2022 was $0.00.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 3 month as first filed | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 6 month as first filed | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-03 | $100.00K 10-Q · filed 2026-08-03 | $180.00K derived: sum of 3 quarters · filed 2026-08-03 | $293.00K derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2026-03-31 | $100.00K 10-Q · filed 2026-05-05 | $180.00K derived: sum of 2 quarters · filed 2026-05-05 | $293.00K derived: sum of 3 quarters · filed 2026-05-05 | $793.00K derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-12-31 | $80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $193.00K derived: sum of 2 quarters · filed 2026-02-24 | $693.00K derived: sum of 3 quarters · filed 2026-08-03 | $208.00K 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $113.00K 10-Q · filed 2025-11-05 | $613.00K derived: sum of 2 quarters · filed 2026-08-03 | $128.00K 10-Q · filed 2025-11-05 | $3.94M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-06-30 | $500.00K 10-Q · filed 2026-08-03 | $458.00K 10-Q · filed 2025-08-06 | $100.00K 10-Q · filed 2026-08-03 | $15.00K 10-Q · filed 2025-08-06 | $3.83M derived: sum of 3 quarters · filed 2026-08-03 | -$1.37M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$400.00K 10-Q · filed 2026-05-05 | -$443.00K 10-Q · filed 2025-05-07 | $3.33M derived: sum of 2 quarters · filed 2026-05-05 | -$1.87M derived: sum of 3 quarters · filed 2026-05-05 | -$279.00K derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$1.47M derived: sum of 2 quarters · filed 2026-02-24 | $121.00K derived: sum of 3 quarters · filed 2026-02-24 | $5.30M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | -$5.20M 10-Q · filed 2025-11-05 | -$3.60M derived: sum of 2 quarters · filed 2025-11-05 | $1.57M 10-Q · filed 2025-11-05 | -$3.99M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | $1.59M 10-Q · filed 2025-08-06 | $6.77M 10-Q · filed 2025-08-06 | $1.21M derived: sum of 3 quarters · filed 2026-02-24 | $4.75M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | $5.18M 10-Q · filed 2025-05-07 | -$383.00K derived: sum of 2 quarters · filed 2026-02-24 | $3.16M derived: sum of 3 quarters · filed 2026-02-24 | $8.84M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | -$5.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$2.02M derived: sum of 2 quarters · filed 2026-02-24 | $3.66M derived: sum of 3 quarters · filed 2026-02-24 | $3.66M 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $3.54M 10-Q · filed 2024-11-07 | $9.22M derived: sum of 2 quarters · filed 2024-11-07 | $9.22M 10-Q · filed 2024-11-07 | $9.22M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-06-30 | $5.68M 10-Q · filed 2024-08-01 | $5.68M 10-Q · filed 2024-08-01 | $5.68M derived: sum of 3 quarters · filed 2025-02-26 | $5.68M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $2.00K derived: sum of 3 quarters · filed 2024-02-28 | -$14.00K 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | $2.00K derived: sum of 2 quarters · filed 2022-11-09 | -$14.00K 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $2.00K 10-Q · filed 2022-08-03 | -$14.00K 10-Q · filed 2022-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |